Double-Barreled CAR-T attack on Hard-to-Treat myeloma shows promise
NCT ID NCT07359014
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing a new type of CAR-T cell therapy that targets two proteins (CD19 and BCMA) on myeloma cells. It is for people whose multiple myeloma has come back or stopped responding to other treatments. The goal is to see if this dual-target approach is safe and can shrink or control the cancer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSE MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Xuzhao Zhang
RECRUITINGHangzhou, 310003, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a One-Two drug punch beat back Hard-to-Treat myeloma?
- Double-barreled CAR t therapy takes aim at hard-to-treat myeloma
- New study examines belantamab combos for myeloma relapse
- New hope for myeloma: adaptive trial tests smarter drug combos
- New drug aims to keep myeloma in check after CAR-T
- New cocktail of drugs aims to tackle returning myeloma